Yuxin Hu
Name: Yuxin Hu
Present position: Director of Department of Radiochemotherapy, Shangrao Cancer Hospital, Jiangxi Province.
Education
Visiting Scientist: Nov., 2007 - Feb., 2008. Department of Clinical Cancer Prevention, MD Anderson Cancer Center, USA
Postdoctoral Fellowship：April, 1996 - April, 1998. Department of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan
Ph.D.：July, 1988 - July, 1993. Department of Gastroenterology, Shanghai Changhai Hospital, Second Military Medical University, China
M.D.: March, 1978 - August, 1982. Anhui Medical University, China
Recent Publications (writing in English only)
1. Hu YX, Hoque AM, Guan BX, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer, Int J Cancer 2011;128:132-143
2. Li Y, Deng L, Yan J, Yang Y, Sun J, Hu YX. Potent antitumor effects of glycolic acid: a preclinical study of an alternative therapy of acetic acid for liver cancer. p16-21, Kanazawa Medical University Press (Japan), March 2010
3. Hu YX, Jiang Y, Yan J, et al. Unusual prostate carcinoma: extensive metastasis, significant rising of serum PSA, and neuroendocrine differentiation: a case report. Chin Med J 2005; 118: 258.
4. Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, et al. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 2003; 38: 663.
5. Hu YX, Li P, Liu BS, et al. Enhanced expression of matrix metalloproteinase 7 in pancreatic carcinoma. 癌症 2000; 19: 52.
6. Hu YX, Watanabe H, Li P, Wang Y, et al. An immunohistochemical analysis of p27 expression in human pancreatic carcinoma. Pancreas 2000; 21: 226.
7. Watanabe H, Ha A, Hu YX, et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract cancer. Cancer 1999; 86:1441.
8. Hu YX, Watanabe H, Ohtsubo K., et al. Expression of Bcl-2 associated with the altered p53 protein and its impact on the progression of pancreatic carcinoma. Br J Cancer 1999; 80: 1075.
9. Watanabe H, Yamaguchi Y, Ha A, Hu YX, et al. Quantitative determination of k-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay. Pancreas 1998; 17: 341.
10. Hu YX, Watanabe H, Ohtsubo K, et al. Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma. Clin Cancer Res 1998; 4: 1147.
11. Hu YX, Watanabe H, Ohtsubo K, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997; 3: 1473.
12, H Taga, H Watanabe, Y Yamaguchi, K Ohtsubo, Ha A, Hu YX, Y Motoo, Okai T, M Mizoguchi, M Ma, Kawashima A, Sawabu N. Large Duodenal Tumor with Positive K-ras Mutation Mimicking Lateral Spreading Tumor of the Colon. Digestive Endoscopy Dig Endosc 1999; 11: 70–75
13. Hu YX, Xu GM. Findings of cholangiopancreatography in pseudotumorous pancreatitis. Chin Med J 1995; 108: 907.